Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · Real-Time Price · USD
0.6100
+0.0252 (4.31%)
At close: May 22, 2026, 4:00 PM EDT
0.6338
+0.0238 (3.90%)
After-hours: May 22, 2026, 7:07 PM EDT
Vivos Therapeutics Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Vivos Therapeutics stock has a consensus rating of "Buy" and an average price target of $2.42. The average 1-year stock price forecast is 296.72% higher than the current stock price, while the lowest is $1.75 (+186.89%) and the highest is $3.00 (+391.80%).
Price Target: $2.42 (+296.72%)
Analyst Consensus: Buy
* Price targets were last updated on Apr 22, 2026.
Analyst Ratings
The average analyst rating for Vivos Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $5.5 → $3 | Strong Buy | Maintains | $5.5 → $3 | +391.80% | Apr 22, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $2.5 | Strong Buy | Maintains | $7 → $2.5 | +309.84% | Apr 17, 2026 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $6.5 → $5.5 | Strong Buy | Maintains | $6.5 → $5.5 | +801.64% | Dec 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +1,047.54% | Nov 17, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $6.2 → $6.5 | Strong Buy | Maintains | $6.2 → $6.5 | +965.57% | Sep 9, 2025 |
Financial Forecast
Revenue This Year
23.04M
from 17.44M
Increased by 32.11%
Revenue Next Year
34.63M
from 23.04M
Increased by 50.27%
EPS This Year
-1.18
from -2.06
EPS Next Year
-0.36
from -1.18
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 |
|---|---|---|
| High | 27.2M | 35.6M |
| Avg | 23.0M | 34.6M |
| Low | 20.4M | 33.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 |
|---|---|---|
| High | 56.1% | 54.7% |
| Avg | 32.1% | 50.3% |
| Low | 17.1% | 44.4% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | -0.84 | -0.37 |
| Avg | -1.18 | -0.36 |
| Low | -1.45 | -0.34 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.